It is observed that diabetics with ischaemic foot ulcers usually developed worst possible chronic skin wounds, along with higher risk of amputation and mortality rates.
Among approximately 180,000 to 200,000 annual amputations in the U.S., it is noted that between 80 and 85 percent are preceded by an ischemic diabetic foot ulcer (DFU).
Ischaemia results when the blood supply to a tissue is greatly reduced or stopped - this can occur in diabetes since it can also cause impaired blood flow in patients.
The researchers at Bristol Heart Institute discovered that a particular type of stem cell – CD133+ cells (derived from human foetal aorta) promoted blood vessel formation in order to salvage the diabetic limb. On a third day follow up researchers observed that transplanted cells have disappeared and already boosted the generation of new vessels.
Researchers, in their early studies found that foetal or embryonic stem cells are more therapeutically effective than adult stem cells while treating mdels of back leg ischaemia.
Foetal stem cells possess a better ability to multiply and to graft onto host tissue, and to separate into other cell types to replace those in the damaged tissue.
The researcher group led by Bristol University’s Professor Madeddu also found that foetal stem cells accelerate the closure of ischaemic diabetic ulcers, while stem cells from blood of adult donors are ineffective.
Experts claimed that this research represents a useful way to help identify new strategies for dealing with type 1 diabetes.